They’re not. So we think Zuranolone with the potential rapid effect. Again, as Laura said, enhances the practice of treating that patient, doesn’t really change how you monitor that patient. You also asked about refills. There will be a variety of ways that refills can happen, some might write scripts around with a refill already. Instructing their patients, and if they’re feeling better for extended period of time, but they’re dark and mood, elevated anxiety and insomnia come back, you know, to refill and try it again. If it doesn’t work, come and see me, I might have other tool for you. More refill can be called into a pharmacy just like any drug today.
Laura Chico: Thanks.
Operator: Moving next to Sumant Kulkarni from Canaccord. Please go ahead.
Sumant Kulkarni: Good morning and thanks for taking my question. So Zuranolone is relatively rapid acting. So either in SHORELINE or in any other setting, do you have data on patients that may have stopped taking the product before completing the full 14-day course of therapy simply because they have to sort of depression had gone away and they were feeling better. I’m asking because this discretionary patient action could have important implications of pricing and potential sampling and the dynamic might lead to large distributions around the per patient, per year pricing that payers are looking at versus maybe selling a flat price?
Barry Greene: Yes, Sumant, thanks for the question. So I’ll ask Jim to talk about specific data. Obviously, when you’re treating over 3,500 patients, it might — there are problems on patients who took a drug for a period of time and stopped, because they’re feeling so better. But that’s been a large part of not what’s happening. Just like if you are prescribed, as you have for your lower respiratory tract infection in total to feel better, but complete the full course. That would be the instruction for Zuranolone. And we don’t really believe there’s going to be much of a dynamic where a patient might take Zuranolone for three or four days and €œsave the rest of their pack€. So there will be instructions to complete the 14-day pack. And the data are supported as those that complete the 2 week and respond — remain responded. So we don’t really think that could give a big dynamic that plays out here.
Operator: We’ll hear next from Yatin Suneja from Guggenheim.
Yatin Suneja: Hey, guys. Thank you for taking my question. Just following up on a question that they asked earlier. So the profile of the drug is short-term and you have a de-scheduling to probably limit your ability to sample. Can you maybe just talk about the relevance of sampling? How could that impact you, especially in the PCP setting? Thanks.
Barry Greene: Yes, Yatin. Thanks for the question. Let me ask Chris to talk about our overall project.
Chris Benecchi: Yes, so from what we’re thinking about, there’s a number of different ways that we think about getting physicians early experience with the medication. While we haven’t communicated yet that we’re going to have an extensive sampling program. There’s a number of different ways to think about this and the team was really thinking through that. We know that from the experience that we’ve seen with investigators is that those physicians that have experience, they recognize the profound impact that Zuranolone have, so it’s not only experience has been critical. With respect to DE scheduling, we don’t anticipate it having a major impact on the way that we think about sampling. While there may be one or two states that may have some language around sampling and sampling stores.
There’s alternative ways to get physicians experience as well. So we don’t see DE scheduling, we see something that would in any way a position and getting early experience. And quite as that, we think that from the vast array of programs that we can employ that really experience is going to be something that’s going to have a profound impact on the launch in meditation.
Operator: Tim Lugo from William Blair has your next question.
